Phase II study of weekly paclitaxel (PAC) and bryostatin-1 (BRYO) in hormone refractory prostate cancer (HRPC)
2005
4714 Background: Augmenting the antitumor activity of taxanes is a logical approach to improve treatment for patients with HRPC. BRYO, an inhibitor of protein kinase C and CDK2 activity, enhances t...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI